BIPSX Performance — Biotechnology UltraSector ProFund, Service Class
Data updated: 2026-10-13
BIPSX returned +26.83% year to date and +110.88% over one year to Jul 2026. Annualised returns are +22.51% over 3 years and +9.47% over 5 years. The fund beat its Trading - Leveraged category average: $100 invested three years ago grew to $184, against $136 for the category, and to $211 over one year, against $105. Volatility over the past three years was 39.26% a year. In the 12 months to Jul 2026 the fund lost a net $16.9M, and assets reached $118.70M.
BIPSX Growth of $100
What $100 invested in Biotechnology UltraSector ProFund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Trading - Leveraged category average over the same months.
| Period | BIPSX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $211 | $105 |
| 3 years (Aug 2023 – Jul 2026) | $184 | $136 |
| 5 years (Aug 2021 – Jul 2026) | $157 | $130 |
| Since data start (Aug 2019 – Jul 2026) | $292 | $147 |
BIPSX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +26.83% |
| 1 year | +110.88% |
| 3 years (annualised) | +22.51% |
| 5 years (annualised) | +9.47% |
BIPSX Annual Returns
Calendar-year total returns of Biotechnology UltraSector ProFund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +26.83% |
| 2025 | +46.51% |
| 2024 | −6.16% |
| 2023 | +8.97% |
| 2022 | −14.29% |
| 2021 | +22.58% |
| 2020 | +18.93% |
| 2019 (Aug–Dec) | +23.16% |
BIPSX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.8% | +2.6% | −0.5% | +3.8% | +5.7% | +23.6% | −11.0% | — | — | — | — | — |
| 2025 | +3.7% | −6.8% | −13.2% | +2.3% | −7.6% | +6.6% | +4.4% | +6.9% | +17.1% | +18.8% | +13.4% | −1.5% |
| 2024 | −3.7% | +18.2% | −5.6% | −16.7% | +7.3% | +5.8% | +9.7% | +2.9% | −4.1% | −3.3% | +3.3% | −14.6% |
| 2023 | +0.2% | −6.5% | −3.1% | +7.5% | +6.8% | −2.1% | +1.3% | −9.2% | −11.6% | −14.5% | +20.5% | +27.5% |
| 2022 | −14.0% | −3.6% | +8.0% | −14.1% | +2.3% | −2.8% | +5.9% | −8.7% | −4.6% | +13.7% | +11.9% | −4.6% |
| 2021 | +8.0% | −2.8% | −1.0% | +6.4% | −0.4% | +9.4% | +5.3% | +6.3% | −10.5% | −0.1% | −3.1% | +4.8% |
| 2020 | −9.5% | +0.9% | −6.3% | +20.0% | +10.6% | +1.7% | 0.0% | −1.5% | −3.4% | −9.4% | +16.5% | +2.5% |
| 2019 | — | — | — | — | — | — | — | −1.6% | −0.2% | +9.9% | +13.4% | +0.6% |
BIPSX Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 39.26%
- 3-year Sharpe ratio: 0.46 (vs 4.5% risk-free rate)
- Best month: +27.51% (Dec 2023)
- Worst month: −16.71% (Apr 2024)
BIPSX Fund Flows
Monthly money in and out of Biotechnology UltraSector ProFund, from SEC Form N-PORT.
- 12-month net flow: −$16.9M
- 12-month gross sales (incl. reinvestments): $218.2M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $19.4M | $21.0M | −$1.7M |
| Jun 2026 | $18.7M | $16.7M | $2.0M |
| May 2026 | $3.7M | $84.2M | −$80.5M |
| Apr 2026 | $12.9M | $12.7M | $173K |
| Mar 2026 | $10.4M | $13.3M | −$2.9M |
| Feb 2026 | $9.9M | $12.6M | −$2.7M |
| Jan 2026 | $20.2M | $26.8M | −$6.6M |
| Dec 2025 | $84.3M | $11.0M | $73.3M |
| Nov 2025 | $17.5M | $11.4M | $6.1M |
| Oct 2025 | $13.0M | $11.4M | $1.6M |
| Sep 2025 | $4.2M | $8.1M | −$3.9M |
| Aug 2025 | $4.1M | $5.9M | −$1.8M |
BIPSX Assets Under Management
Net assets of Biotechnology UltraSector ProFund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $118.70M |
| 2026-04-30 | $182.58M |
| 2026-01-31 | $177.37M |
| 2025-10-31 | $87.62M |
| 2025-07-31 | $62.77M |
| 2025-04-30 | $66.23M |
| 2025-01-31 | $84.89M |
| 2024-10-31 | $100.49M |
| 2024-07-31 | $108.76M |
| 2024-04-30 | $94.51M |
| 2024-01-31 | $106.44M |
| 2023-10-31 | $77.10M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.